Daniel W. Young

Daniel W. Young, PhD

Shareholder | Biotechnology
617.646.8245 Daniel.Young@WolfGreenfield.com LinkedIn Profile

Education

  • Massachusetts Maritime Academy, BS, Marine Engineering
  • Worcester Polytechnic Institute, MEng, Biomedical Engineering
  • University of Massachusetts Medical School, PhD, Biomedical Science
  • Suffolk University Law School, JD, cum laude, Intellectual Property Law Concentration, with distinction

Key Technologies

  • Cell-Based Therapies
  • Nucleic Acid-Based Therapies
  • Immuno-Oncology Approaches
  • Antibodies
  • Vaccines
  • Gene Therapies
  • Genomics
  • Bioinformatics
  • Biomedical Devices
  • Marine Technologies
  • Clean Energy Technologies

Practice Groups

Admitted to Practice

  • Massachusetts
  • US Patent and Trademark Office

Location

  • Boston

Overview

Dan Young works with clients across a broad range of technology areas to develop and implement IP strategies that are aligned with their business goals through portfolio management, patent prosecution, due diligence support, and third-party IP evaluations, focusing primarily in the areas of cell-based therapies, nucleic acid-based therapies, immuno-oncology approaches, antibodies, vaccines, gene therapies, genomics and bioinformatics, biomedical devices, and marine and clean energy technologies. 

A recipient of a Novartis Presidential Post-Doctoral Fellowship, Dan did his post-doctoral research at the Novartis Institute for BioMedical Research and in the Mitchison Lab in the Department of Systems Biology at Harvard Medical School. During this time, he was involved in an image-based genome-wide RNAi screen, and developed computational approaches to profile small-molecule libraries using multidimensional cell-based assays for lead discovery and characterization. Dan’s doctoral work focused on understanding molecular mechanisms of tissue-specific gene regulation, and involved use of chromatin assays, gene profiling, and novel imaging techniques to elucidate epigenetic mechanisms of tissue-specific transcriptional control during cell growth and differentiation. During his master’s studies, Dan investigated the poroelastic material properties of bone tissue.

Before entering graduate school, Dan worked for several years as a mechanical engineer in the Hydraulics Laboratory at FMGlobal Research and as a licensed engineering officer in the United States Merchant Marine. Dan served as an operating engineer aboard steam turbine and diesel powered vessels in the Great Lakes and Mediterranean Sea. With this background, Dan also helps clients having patent matters unique to the maritime industry.

Dan is co-inventor of a US patent related to microscopic image analysis technology, and has co-authored more than 35 scientific research and review articles, including in Nature, Nature Chemical Biology, Nature Reviews Genetics, Nature Reviews Drug Discovery, and Proceedings of the National Academy of Sciences. One of Dan’s articles was voted “Must Read” by the Faculty of 1000 Biology.


Experience

  • Assisted corporate biotech fund with IP due diligence analysis of startup biopharmaceutical company.
  • Conducted IP diligence in connection with a corporate transaction involving a immuno-oncology company having an antibody screening and development platform.
  • Prepared non-infringement opinions relating to antibody-based diagnostic assays for cancer detection.
  • Developed and implemented an IP strategy for a start-up biotherapeutics company for domestic and foreign patent protection, and provided due diligence support through multiple rounds of financing.
  • Advised a start-up molecular diagnostics company with developing and implementing an overall patent strategy to help position it for a venture financing. 
  • Prepared and filed a series of patent applications for a local university to capture innovations relating to a therapeutic vaccine technology, which became founding IP for a venture backed start-up company. 
  • Co-authored an Amicus Brief on behalf of the Boston Patent Law Association that was filed with the Supreme Court of the United States in connection with Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12-398 (2013).

Activities

  • President, Boston Patent Law Association (BPLA)

Recognition

  • Recognized on the inaugural Best Lawyers: Ones to Watch list by The Best Lawyers in America©
  • Repeatedly named to the list of Massachusetts Rising Stars by Super Lawyers
  • Sigma Xi
  • Phi Delta Phi

Recent News

See All News

Events